Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

Rhea-AI Summary

Absci (Nasdaq: ABSI) will report business updates and first quarter 2026 financial and operating results after market close on May 7, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT. Live audio and a replay will be available on the company investor relations website.

News Market Reaction – ABSI

-0.76%

22 alerts

-0.76% Session close to close

+4.2% Peak in 4 hr 57 min

$611.32M Market Cap

0.7x Rel. Volume

In the Apr 24 session, ABSI declined 0.76%, reflecting a mild negative market reaction. Argus tracked a peak move of +4.2% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets expectations for Q1 2026 results on May 7, 2026 with a webcast and replay. It...

Analysis

This announcement sets expectations for Q1 2026 results on May 7, 2026 with a webcast and replay. It follows disclosures of 2025 revenue of $2.8 million, R&D spending of $81.4 million, and a net loss of $115.2 million, alongside cash of $144.3 million. Investors may focus on updated cash runway, ABS-201 progress, and any use or plans related to the existing $400,000,000 shelf registration when results are reported.

Key Figures

2025 Revenue: $2.8 million 2024 Revenue: $4.5 million 2025 R&D Expense: $81.4 million +5 more

8 metrics

2025 Revenue $2.8 million Full-year 2025; down from $4.5 million in 2024

2024 Revenue $4.5 million Full-year 2024 partner program revenue baseline

2025 R&D Expense $81.4 million Full-year 2025; up from $63.9 million in 2024

2025 Net Loss $115.2 million Full-year 2025; wider than $103.1 million in 2024

Cash & Securities $144.3 million As of December 31, 2025; company cites runway into 1H 2028

Shelf Capacity $400,000,000 Preliminary Form S-3 shelf filed August 12, 2025

Non-affiliate Equity Value $303.8 million Aggregate market value as of June 30, 2025

Shares Outstanding 153,021,263 Common shares outstanding as of March 6, 2026

Previous Earnings date Reports

1 past event · Latest: Feb 24 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 24	Earnings date notice	Neutral	+2.3%	Set date and webcast details for Q4 and full-year 2025 results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Limited history for ‘earnings date’ notices: the prior event saw a modest positive move of 2.26% after the announcement.

Recent Company History

Recent news for Absci has focused on advancing ABS-201 and strengthening leadership. On Mar 24, 2026, full-year 2025 results highlighted clinical progress but also widening losses and higher R&D spend. A new CMO and advisory board were announced in early March, alongside inducement grants. Today’s earnings-date notice on May 7, 2026 fits the established pattern of pre-announcing result dates with a webcast and replay via the investor relations site.

Key Terms

generative AI

1 terms

generative AI technical

"advancing breakthrough therapeutics designed with generative AI, today announced..."

Generative AI is a type of computer technology that can create new content, like text, images, or music, on its own. It’s important because it can produce realistic and useful material quickly, which could change how we create art, write stories, or even develop new products. Think of it as a smart robot that can invent and produce things almost like a human.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the first quarter 2026 after market close on Thursday, May 7, 2026.

Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.

Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.

About Absci

Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.

Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.

Investor Contact
Alexander D.H. Khan
Corporate Vice President, Head of Investor Relations
investors@absci.com 

Media Contact
press@absci.com 

FAQ

When will Absci (ABSI) release its Q1 2026 results and what time is the conference call?

Absci will release Q1 2026 results after market close on May 7, 2026 with a conference call at 4:30 p.m. ET / 1:30 p.m. PT. According to the company, management will discuss business developments, financial and operating results, and outlook during the webcast.

Where can investors listen to the Absci (ABSI) May 7, 2026 webcast and replay?

Investors can access the live audio webcast and archived replay on the company's investor relations site at investors.absci.com. According to the company, the webcast will be archived and available for replay after the event for on-demand listening.

What topics will Absci (ABSI) management cover on the May 7, 2026 call?

Management will discuss business developments, financial and operating results, and outlook during the call. According to the company, the webcast is intended to provide updates on recent corporate progress and first quarter 2026 performance metrics.

How can shareholders prepare questions for Absci's (ABSI) Q1 2026 conference call on May 7, 2026?

Shareholders should review Absci's recent disclosures and prepare concise questions about operations, financials, or guidance. According to the company, the conference call will include management commentary and may offer a Q&A segment following prepared remarks.

Will the Absci (ABSI) May 7, 2026 webcast be available for replay, and for how long?

Yes, the webcast will be archived and available for replay on the investor relations website after the event. According to the company, the archived audio will remain accessible on investors.absci.com, though no specific removal date was provided.